20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 1 of 7

Topic	Participants	Replies	Views	Activity
About the Oral incretins category Compounds › Oral incretins oral semaglutide orforglipron PIONEER programme Pinned Wiki Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	6.2k	20d
About the Other compounds category Compounds › Other compounds research use only custom synthesis needs a source Pinned Wiki Closed Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+8	12	51k	7mo
Research-use-only status: what it means legally and practically — does this still hold? Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Pinned Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…		2	309	9mo
About the Semaglutide category Compounds › Semaglutide semaglutide STEP programme SELECT trial Pinned Wiki Closed GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…		4	4.2k	11mo
About the Cagrilintide & amylin analogues category Compounds › Cagrilintide & amylin analogues cagrilintide cagrisema amylin analogues Pinned Wiki Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	1.8k	11mo
About the Repair & healing peptides category Compounds › Repair & healing peptides BPC-157 TB-500 observational data Pinned Wiki BPC-157, TB-500 and similar. Mostly preclinical evidence; this subcategory is strict about not overstating it. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	19k	13mo
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
About the Secretagogues & GH axis category Compounds › Secretagogues & GH axis GHRP class CJC-1295 ipamorelin Pinned Wiki Closed Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+6	10	1.1k	14mo
About the Retatrutide category Compounds › Retatrutide retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Compounds › Retatrutide randomised trial effect size TRIUMPH programme retatrutide Solved Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…	+43	47	5.5k	just now
Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide SELECT trial type 2 diabetes semaglutide Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-1 ( N…	+29	35	4.4k	1h
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…	+47	53	6.9k	2h
Reading a rodent study on a secretagogue without over-extrapolating — the long version Compounds › Secretagogues & GH axis observational data tesamorelin ipamorelin needs a source Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+59	66	30k	4h
What TRIUMPH is designed to answer, and why we should not pre-empt it Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Solved What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…	+4	8	142	6h
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h
SURPASS-2 and the comparator dose question that will not go away — what changed since Compounds › Tirzepatide SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…	+2	6	5.5k	7h
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…	+3	7	26k	7h
The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins orforglipron oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…		2	7.1k	9h
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited…	+5	9	1.6k	15h
Molecular mass of semaglutide and why the figure differs between sources Compounds › Semaglutide SELECT trial effect size semaglutide STEP programme Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+101	110	12k	16h
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+10	14	8.4k	16h
Stability of BPC-157 in solution: what has been measured — one year on Compounds › Repair & healing peptides needs a source observational data preprint BPC-157 On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…	+84	98	7.8k	18h
What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…	+16	20	23k	19h
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Compounds › Other compounds research use only needs a source mislabelling Solved The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…	+7	11	31k	19h
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…	+40	45	3.4k	21h
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h
Why cagrilintide alone is discussed so much less than in combination — does this still hold? Compounds › Cagrilintide & amylin analogues cagrisema randomised trial cagrilintide effect size Solved Under review Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…	+27	31	1.2k	22h
CJC-1295 with and without DAC: what the modification does Compounds › Secretagogues & GH axis needs a source tesamorelin CJC-1295 GHRP class On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…	+117	123	5.6k	22h
What would change my mind about repair peptides: a specific answer Compounds › Repair & healing peptides TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…	+26	30	1.1k	23h

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →